Aiguade Bosch
Jose Aiguade Bosch, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20080275038 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists - The present disclosure relates to imidazopyridine derivatives of formula (I): | 11-06-2008 |
20100105723 | 5-PHENYL-6-PYRIDIN-4-YL-1,3-DIHYDRO-2H-IMIDAZO[4,5-b]PYRIDIN-2-ONE DERIVATIVES USEFUL AS A2B ADENOSINE RECEPTOR ANTAGONISTS - The present disclosure relates to compounds of formula (I): | 04-29-2010 |
20140303127 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES - The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies. | 10-09-2014 |
20140378421 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES - The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies. | 12-25-2014 |
Jose Aiguade Bosch, Sant Feliu De Llobregat ES
Patent application number | Description | Published |
---|---|---|
20130053359 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES - The present disclosure relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies. | 02-28-2013 |
Jose Aiguade Bosch, Sant Feliu Dellobregat, Barcelona ES
Patent application number | Description | Published |
---|---|---|
20130281415 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES - The present disclosure relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies. | 10-24-2013 |